- Home
- NGD vs HRMY Comparison
NGD vs HRMY Comparison
Compare NGD & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGD
- HRMY
- Stock Information
- Founded
- NGD N/A
- HRMY 2017
- Country
- NGD Canada
- HRMY United States
- Employees
- NGD N/A
- HRMY N/A
- Industry
- NGD
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- NGD
- HRMY Health Care
- Exchange
- NGD Nasdaq
- HRMY Nasdaq
- Market Cap
- NGD 2.0B
- HRMY 1.9B
- IPO Year
- NGD 2004
- HRMY 2020
- Fundamental
- Price
- NGD $2.51
- HRMY $34.28
- Analyst Decision
- NGD Buy
- HRMY Buy
- Analyst Count
- NGD 4
- HRMY 10
- Target Price
- NGD $3.04
- HRMY $49.80
- AVG Volume (30 Days)
- NGD 8.5M
- HRMY 601.0K
- Earning Date
- NGD 02-11-2025
- HRMY 10-29-2024
- Dividend Yield
- NGD N/A
- HRMY N/A
- EPS Growth
- NGD N/A
- HRMY N/A
- EPS
- NGD 0.02
- HRMY 2.11
- Revenue
- NGD $861,500,000.00
- HRMY $681,879,000.00
- Revenue This Year
- NGD $22.53
- HRMY $24.79
- Revenue Next Year
- NGD $31.05
- HRMY $17.98
- P/E Ratio
- NGD $98.83
- HRMY $16.28
- Revenue Growth
- NGD 14.85
- HRMY 25.83
- 52 Week Low
- NGD $1.09
- HRMY $28.14
- 52 Week High
- NGD $3.25
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- NGD 38.03
- HRMY 53.15
- Support Level
- NGD $2.47
- HRMY $33.01
- Resistance Level
- NGD $3.08
- HRMY $34.82
- Average True Range (ATR)
- NGD 0.12
- HRMY 1.16
- MACD
- NGD -0.04
- HRMY 0.12
- Stochastic Oscillator
- NGD 5.74
- HRMY 71.10
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.